RIA: Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer

Sponsor
Grupo Espanol Multidisciplinario del Cancer Digestivo (Other)
Overall Status
Completed
CT.gov ID
NCT02340949
Collaborator
Pivotal S.L. (Industry)
180
2
61.1

Study Details

Study Description

Brief Summary

This trial compares induction treatment with FOLFOX with or without aflibercept in a high risk population selected by MRI, prior to receiving standard chemoradiation (capecitabine combined with 50.4 Gy in 28 days) and surgery, in order to evaluate the efficacy in terms of pathologic complete response (pCR).

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

This is a randomized trial comparing induction treatment with FOLFOX with or without aflibercept in a high risk population selected by MRI, prior to receiving standard chemoradiation (capecitabine combined with 50.4 Gy in 28 days) and surgery. Once it is confirmed that the subjects fulfill the eligibility criteria (MRI-defined high risk RC), and have signed the informed consent, a central review will be requested to confirm clinical stage, and then they will be randomized to receive mFOLFOX6 + Aflibercept or mFOLFOX6 (without Aflibercept).

Random assignment of treatment will be stratified by T3 versus T4 stage. All the patients enrolled in the study will receive one cycle of study medication (mFOLFOX6 with or without aflibercept) every 14 days for six cycles, unless unacceptable toxicity or progression is detected. After this treatment, patients will receive standard chemo-radiotherapy (CT/RT) (capecitabine 825 mg/m2 twice daily combined with a total dose of 50.4 Gy in 28 days) followed by surgery, provided they have not progressed.

Patients with progression disease during the treatment phase will be withdrawn from the study and will receive their treatment according to the investigator's judgment. If a patient withdraws consent and refuses to receive further treatment, the patient must be followed up for 3 years from randomization or until progression, to evaluate disease-free survival. If a patient withdraws consent and refuses to continue in the study, the follow-up evaluations must be discontinued.

Study Design

Study Type:
Interventional
Actual Enrollment :
180 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer. Phase II Randomized, Multicenter, Open Label Trial
Study Start Date :
Jan 1, 2015
Actual Primary Completion Date :
Jul 15, 2019
Actual Study Completion Date :
Feb 4, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: mFOLFOX6 + Aflibercept

- mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme: Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m². - Aflibercept, will be administered intravenously (I.V.) at doses of 4 mg/Kg on Day 1 every 14 days. Aflibercept will be supplied to sites by the study Sponsor as 4 ml vials at a concentration of 25 mg/ml. Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs.

Drug: Aflibercept
Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml
Other Names:
  • ZALTRAP
  • Drug: 5-Fluoruracil
    Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2
    Other Names:
  • 5-FU
  • Drug: Oxaliplatin
    Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU
    Other Names:
  • Any marketed
  • Drug: Leucovorin
    Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
    Other Names:
  • Any marketed
  • Active Comparator: mFOLFOX6

    - mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme: Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m². Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs.

    Drug: 5-Fluoruracil
    Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2
    Other Names:
  • 5-FU
  • Drug: Oxaliplatin
    Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU
    Other Names:
  • Any marketed
  • Drug: Leucovorin
    Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
    Other Names:
  • Any marketed
  • Outcome Measures

    Primary Outcome Measures

    1. Number of Patients Achieving Pathologic Complete Response (pCR). [From baseline until 2 years and 2 months]

      The number of patients achieving pCR after induction therapy with mFOLFOX6 +/- aflibercept followed by chemotherapy (CT)/radiotherapy (RT). pCR will be defined as the absence of viable tumor cells in the primary tumor and in the lymph nodes (T0N0)

    Secondary Outcome Measures

    1. Number of Patients Achieving Pathological Parameters of Efficacy: R0 Resection, Tumor Regression Grade, and Circular Radial Margin Rate [From baseline until 2 years and 2 months]

      R0 resection is defined as complete tumor removal, and correlates with good prognosis. Tumor regression grade (TRG) is defined as presence of residual tumor after preoperative therapy. This was assessed by magnetic resonance imaging (MRI) according to the 5-point regression grading scale established by Mandard: TRG1 (complete response with no residual cancer), TRG2 (rare residual cancer), TRG3 (fibrosis outgrowing residual cancer), TRG4 (residual cancer outgrowing fibrosis) and TRG5 (absence of regression). Circular Radial Margin (CRM) is defined as the distance from the margin of normal tissue to the edge of tumor tissue in the resected primary tumor the measured by histopathology study after surgery. A margin of ≤1 mm is considered to be a negative prognostic factor for local recurrence.

    2. Number of Participants With Significant MRI Changes Post Intervention, as Defined by T Downstaging [From baseline until 2 years and 2 months]

      Tumor size is assessed by MRI to determine the T stage. T Downstaging: defined as a lower pathologic T stage compared to pre-treatment T stage.

    3. Number of Patients Reporting Adverse Events (AEs) [From baseline until 2 years and 2 months]

      The safety and tolerability of the study therapy were assessed by means of AEs and changes in laboratory data. AEs were coded and evaluated using the NCI-CTCAE v4.0 toxicity criteria (if NCI-CTCAE are not applicable, MedDRA was used).

    4. Number of Patients Reporting Surgical Complications [From surgical intervention up to 30 days post-surgery, within a general time frame of 2 years and 2 months per study protocol]

      Surgical complications will be assessed by means of AEs reported during 30 days post surgery.

    5. Disease Free Survival (DFS) Rate at 3 Years [At 3 years after study treatment completion, within a general time frame of 5 years and two months]

      DFS rate is defined as the percentage of participants without local recurrences at 3-years post study treatment. Here we report the DFS rate at 3-years after completing the Study treatment.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 69 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Signed and dated informed consent, and willing and able to comply with protocol requirement;

    2. Male or female subjects with rectal cancer ≥18 and <70 years of age;

    3. High risk MRI-defined operable rectal cancer (with an inferior margin no more than 12 cm above the anal verge as assessed by MRI). Presence of at least 1 of the following on high resolution, thin-slice MRI (3 mm):

    Middle Third Tumors

    • mr T3
    1. Extramural vascular invasion (EMVI) positive

    2. Extramural extension > 5 mms into perirectal fat

    3. Mesorectal fascia (MRF) threatened or involved*

    • mr T4***

    Distal Third Tumors (≤5 cm from anal verge)

    • mr T3 tumor at or below levators

    • T4 as above N2**

    • tumor or lymph node < 1 mm from the mesorectal fascia **≥4 lymph nodes in the mesorectum showing morphological signs on MRI indicating metastatic disease. ≥4 nodes, whether enlarged or not, with a rounded, homogeneous appearance is thus not sufficient.

    • T4a: overgrowth to an adjacent organ or structure or T4b: peritoneal involvement.

    1. Histologically confirmed adenocarcinoma of the rectum. All other histological types are excluded;

    2. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤1;

    3. Hematological status: neutrophils (ANC) ≥1.5x109/L; platelets ≥100x109/L; hemoglobin ≥9g/dL;

    4. Adequate renal function: serum creatinine level <1.5 x upper limit of normality (ULN);

    5. Adequate liver function: serum bilirubin ≤1.5 x ULN, alkaline phosphatase <5x ULN, AST/ALT < 3 x ULN;

    6. Proteinuria <2+ (dipstick urinalysis) or ≤1g/24hour;

    7. Regular follow-up feasible;

    8. For female patients of childbearing potential, negative serum pregnancy test within 1 week (7 days) prior to starting study treatment;

    9. Female patients must commit to using reliable and appropriate methods of contraception until at least three months after the end of study treatment (when applicable). Male patients with a partner of childbearing potential must agree to use contraception in addition to having their partner use another contraceptive method during the trial.

    Exclusion Criteria:
    1. Prior treatment with aflibercept;

    2. History or evidence upon physical examination of metastasis;

    3. Uncontrolled hypercalcemia;

    4. Pre-existing permanent neuropathy (NCI grade ≥2);

    5. Uncontrolled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy;

    6. Concomitant protocol unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy);

    7. Treatment with any other investigational medicinal product within 28 days prior to study entry;

    8. Other concomitant or previous malignancy, except: i/ adequately treated in-situ carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin, iii/ cancer in complete remission for >5 years;

    9. Any other serious and uncontrolled non-malignant disease, major surgery or traumatic injury within the last 28 days;

    10. Pregnant or breastfeeding women;

    11. Patients with known allergy to any excipient to study drugs;

    12. History of myocardial infarction and/or stroke within 6 months prior to randomization; Previous history of stable angina, uncontrolled arrhythmia, and acute coronary syndrome even if controlled with medication or with myocardial infarction within the last 12 months.

    13. Bowel obstruction.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Grupo Espanol Multidisciplinario del Cancer Digestivo
    • Pivotal S.L.

    Investigators

    • Study Director: Carlos Fernández-Martos, MD, Fundación Instituto Valenciano de Oncología
    • Principal Investigator: Antonieta Salud Salvia, MD, Hospital Universitari Arnau de Vilanova de Lleida
    • Principal Investigator: Carles Pericay Pijaume, MD, Hospital de Sabadell - Parc Taulí
    • Principal Investigator: Clara Montagut, MD, Hospital del Mar
    • Principal Investigator: Joan Maurel Santasusana, MD, Hospital Clinic i provincial de Barcelona
    • Principal Investigator: Vicente Alonso Orduña, MD, Hospital Miguel Servet
    • Principal Investigator: Ruth Vera García, MD, Complejo Hospitalario de Navarra
    • Principal Investigator: Javier Gallego Plazas, MD, Hospital General Universitario de Elche
    • Principal Investigator: Núria Rodríguez Salas, MD, Hospital Universitario La Paz
    • Principal Investigator: Antonio Cubillo, MD, Hospital Universitario Madrid Sanchinarro (CIOCC)
    • Principal Investigator: Bertomeu Massuti, MD, Hospital General Universitario de Alicante
    • Principal Investigator: Ferrán Losa, MD, Hospital de Sant Joan Despí Moisés Broggi
    • Principal Investigator: Miguel Nogué, MD, Hospital General de Granollers
    • Principal Investigator: Jaume Capdevila, MD, Hospital Universitari Vall d'Hebrón
    • Principal Investigator: Isabel Busquier, MD, Consorcio Hospitalario Provincial de Castellón
    • Principal Investigator: Inma Guash Jordan, MD, Fundación Althaia Manresa
    • Principal Investigator: Laura Layos Romero, MD, Hospital Universitari Germans Trias i Pujol de Badalona
    • Principal Investigator: Marta Martín-Richard, MD, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
    • Principal Investigator: Rocio García Carbonero, MD, Hospital Universitario 12 de Octubre
    • Principal Investigator: Carlos López López, MD, Hospital Universitario Marqués de Valdecilla

    Study Documents (Full-Text)

    More Information

    Publications

    None provided.
    Responsible Party:
    Grupo Espanol Multidisciplinario del Cancer Digestivo
    ClinicalTrials.gov Identifier:
    NCT02340949
    Other Study ID Numbers:
    • GEMCAD-1402
    First Posted:
    Jan 19, 2015
    Last Update Posted:
    May 3, 2021
    Last Verified:
    Apr 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Additional relevant MeSH terms:

    Study Results

    Participant Flow

    Recruitment Details
    Pre-assignment Detail
    Arm/Group Title mFOLFOX6 + Aflibercept mFOLFOX6
    Arm/Group Description - mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme: Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m². - Aflibercept, will be administered intravenously (I.V.) at doses of 4 mg/Kg on Day 1 every 14 days. Aflibercept will be supplied to sites by the study Sponsor as 4 ml vials at a concentration of 25 mg/ml. Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs. Aflibercept: Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml 5-Fluoruracil: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2 Oxaliplatin: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU Leucovorin: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU - mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme: Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m². Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs. 5-Fluoruracil: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2 Oxaliplatin: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU Leucovorin: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
    Period Title: Overall Study
    STARTED 115 65
    COMPLETED 99 61
    NOT COMPLETED 16 4

    Baseline Characteristics

    Arm/Group Title mFOLFOX6 + Aflibercept mFOLFOX6 Total
    Arm/Group Description - mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme: Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m². - Aflibercept, will be administered intravenously (I.V.) at doses of 4 mg/Kg on Day 1 every 14 days. Aflibercept will be supplied to sites by the study Sponsor as 4 ml vials at a concentration of 25 mg/ml. Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs. Aflibercept: Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml 5-Fluoruracil: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2 Oxaliplatin: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU Leucovorin: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU - mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme: Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m². Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs. 5-Fluoruracil: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2 Oxaliplatin: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU Leucovorin: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU Total of all reporting groups
    Overall Participants 115 65 180
    Age (years) [Mean (Standard Deviation) ]
    Mean (Standard Deviation) [years]
    58.4
    (10.4)
    62.2
    (9.2)
    59.7
    (10)
    Sex: Female, Male (Count of Participants)
    Female
    38
    33%
    26
    40%
    64
    35.6%
    Male
    77
    67%
    39
    60%
    116
    64.4%
    Race and Ethnicity Not Collected (Count of Participants)
    Count of Participants [Participants]
    0
    0%
    Region of Enrollment (Count of Participants)
    Spain
    115
    100%
    65
    100%
    180
    100%
    Clinical stage Tumor-nodes-metastasis (TNM) (Count of Participants)
    Mising
    1
    0.9%
    1
    1.5%
    2
    1.1%
    mrT2
    1
    0.9%
    0
    0%
    1
    0.6%
    mrT3
    17
    14.8%
    12
    18.5%
    29
    16.1%
    mrT3B
    8
    7%
    8
    12.3%
    16
    8.9%
    mrT3A
    1
    0.9%
    0
    0%
    1
    0.6%
    mrT3C
    47
    40.9%
    22
    33.8%
    69
    38.3%
    mrT3D
    7
    6.1%
    4
    6.2%
    11
    6.1%
    mrT4
    9
    7.8%
    6
    9.2%
    15
    8.3%
    mrT4A
    16
    13.9%
    7
    10.8%
    23
    12.8%
    mrT4B
    8
    7%
    5
    7.7%
    13
    7.2%
    Count of Patients Which Had a Baseline Clinical Stage TNM Nodes (n2) (Count of Participants)
    Count of Participants [Participants]
    115
    100%
    65
    100%
    180
    100%
    Location (Count of Participants)
    Distal
    30
    26.1%
    18
    27.7%
    48
    26.7%
    Middle
    84
    73%
    46
    70.8%
    130
    72.2%
    Missing
    1
    0.9%
    1
    1.5%
    2
    1.1%
    Histology (Count of Participants)
    Adenocarcinoma
    115
    100%
    65
    100%
    180
    100%
    other
    0
    0%
    0
    0%
    0
    0%
    Mesorectal Fascia (FMR) (Count of Participants)
    FMR + (distance <=1 mm)
    68
    59.1%
    37
    56.9%
    105
    58.3%
    NR
    47
    40.9%
    28
    43.1%
    75
    41.7%
    EMVI score (Count of Participants)
    Score 0/1/2
    60
    52.2%
    34
    52.3%
    94
    52.2%
    Score 3/4
    55
    47.8%
    31
    47.7%
    86
    47.8%

    Outcome Measures

    1. Primary Outcome
    Title Number of Patients Achieving Pathologic Complete Response (pCR).
    Description The number of patients achieving pCR after induction therapy with mFOLFOX6 +/- aflibercept followed by chemotherapy (CT)/radiotherapy (RT). pCR will be defined as the absence of viable tumor cells in the primary tumor and in the lymph nodes (T0N0)
    Time Frame From baseline until 2 years and 2 months

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title mFOLFOX6 + Aflibercept mFOLFOX6
    Arm/Group Description - mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme: Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m². - Aflibercept, will be administered intravenously (I.V.) at doses of 4 mg/Kg on Day 1 every 14 days. Aflibercept will be supplied to sites by the study Sponsor as 4 ml vials at a concentration of 25 mg/ml. Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs. Aflibercept: Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml 5-Fluoruracil: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2 Oxaliplatin: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU Leucovorin: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU - mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme: Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m². Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs. 5-Fluoruracil: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2 Oxaliplatin: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU Leucovorin: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
    Measure Participants 115 65
    Yes
    25
    21.7%
    9
    13.8%
    No
    90
    78.3%
    56
    86.2%
    2. Secondary Outcome
    Title Number of Patients Achieving Pathological Parameters of Efficacy: R0 Resection, Tumor Regression Grade, and Circular Radial Margin Rate
    Description R0 resection is defined as complete tumor removal, and correlates with good prognosis. Tumor regression grade (TRG) is defined as presence of residual tumor after preoperative therapy. This was assessed by magnetic resonance imaging (MRI) according to the 5-point regression grading scale established by Mandard: TRG1 (complete response with no residual cancer), TRG2 (rare residual cancer), TRG3 (fibrosis outgrowing residual cancer), TRG4 (residual cancer outgrowing fibrosis) and TRG5 (absence of regression). Circular Radial Margin (CRM) is defined as the distance from the margin of normal tissue to the edge of tumor tissue in the resected primary tumor the measured by histopathology study after surgery. A margin of ≤1 mm is considered to be a negative prognostic factor for local recurrence.
    Time Frame From baseline until 2 years and 2 months

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title mFOLFOX6 + Aflibercept mFOLFOX6
    Arm/Group Description - mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme: Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m². - Aflibercept, will be administered intravenously (I.V.) at doses of 4 mg/Kg on Day 1 every 14 days. Aflibercept will be supplied to sites by the study Sponsor as 4 ml vials at a concentration of 25 mg/ml. Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs. Aflibercept: Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml 5-Fluoruracil: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2 Oxaliplatin: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU Leucovorin: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU - mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme: Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m². Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs. 5-Fluoruracil: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2 Oxaliplatin: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU Leucovorin: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
    Measure Participants 115 65
    Yes
    101
    87.8%
    60
    92.3%
    No
    2
    1.7%
    2
    3.1%
    Not available
    12
    10.4%
    3
    4.6%
    Yes
    59
    51.3%
    30
    46.2%
    No
    56
    48.7%
    35
    53.8%
    Not available
    0
    0%
    0
    0%
    Yes
    3
    2.6%
    3
    4.6%
    No
    96
    83.5%
    56
    86.2%
    Not available
    16
    13.9%
    6
    9.2%
    3. Secondary Outcome
    Title Number of Participants With Significant MRI Changes Post Intervention, as Defined by T Downstaging
    Description Tumor size is assessed by MRI to determine the T stage. T Downstaging: defined as a lower pathologic T stage compared to pre-treatment T stage.
    Time Frame From baseline until 2 years and 2 months

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title mFOLFOX6 + Aflibercept mFOLFOX6
    Arm/Group Description - mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme: Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m². - Aflibercept, will be administered intravenously (I.V.) at doses of 4 mg/Kg on Day 1 every 14 days. Aflibercept will be supplied to sites by the study Sponsor as 4 ml vials at a concentration of 25 mg/ml. Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs. Aflibercept: Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml 5-Fluoruracil: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2 Oxaliplatin: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU Leucovorin: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU - mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme: Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m². Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs. 5-Fluoruracil: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2 Oxaliplatin: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU Leucovorin: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
    Measure Participants 115 65
    Yes
    68
    59.1%
    46
    70.8%
    No
    47
    40.9%
    19
    29.2%
    4. Secondary Outcome
    Title Number of Patients Reporting Adverse Events (AEs)
    Description The safety and tolerability of the study therapy were assessed by means of AEs and changes in laboratory data. AEs were coded and evaluated using the NCI-CTCAE v4.0 toxicity criteria (if NCI-CTCAE are not applicable, MedDRA was used).
    Time Frame From baseline until 2 years and 2 months

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title mFOLFOX6 + Aflibercept mFOLFOX6
    Arm/Group Description - mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme: Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m². - Aflibercept, will be administered intravenously (I.V.) at doses of 4 mg/Kg on Day 1 every 14 days. Aflibercept will be supplied to sites by the study Sponsor as 4 ml vials at a concentration of 25 mg/ml. Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs. Aflibercept: Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml 5-Fluoruracil: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2 Oxaliplatin: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU Leucovorin: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU - mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme: Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m². Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs. 5-Fluoruracil: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2 Oxaliplatin: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU Leucovorin: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
    Measure Participants 115 65
    Yes
    115
    100%
    65
    100%
    No
    0
    0%
    0
    0%
    Yes
    83
    72.2%
    31
    47.7%
    No
    32
    27.8%
    34
    52.3%
    Yes
    20
    17.4%
    4
    6.2%
    No
    95
    82.6%
    61
    93.8%
    Yes
    3
    2.6%
    0
    0%
    No
    112
    97.4%
    65
    100%
    Yes
    45
    39.1%
    16
    24.6%
    No
    70
    60.9%
    49
    75.4%
    Yes
    105
    91.3%
    59
    90.8%
    No
    10
    8.7%
    6
    9.2%
    Yes
    64
    55.7%
    17
    26.2%
    No
    51
    44.3%
    48
    73.8%
    Yes
    0
    0%
    0
    0%
    No
    115
    100%
    65
    100%
    Yes
    17
    14.8%
    3
    4.6%
    No
    98
    85.2%
    62
    95.4%
    Yes
    25
    21.7%
    3
    4.6%
    No
    90
    78.3%
    62
    95.4%
    5. Secondary Outcome
    Title Number of Patients Reporting Surgical Complications
    Description Surgical complications will be assessed by means of AEs reported during 30 days post surgery.
    Time Frame From surgical intervention up to 30 days post-surgery, within a general time frame of 2 years and 2 months per study protocol

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title mFOLFOX6 + Aflibercept mFOLFOX6
    Arm/Group Description - mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme: Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m². - Aflibercept, will be administered intravenously (I.V.) at doses of 4 mg/Kg on Day 1 every 14 days. Aflibercept will be supplied to sites by the study Sponsor as 4 ml vials at a concentration of 25 mg/ml. Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs. Aflibercept: Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml 5-Fluoruracil: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2 Oxaliplatin: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU Leucovorin: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU - mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme: Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m². Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs. 5-Fluoruracil: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2 Oxaliplatin: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU Leucovorin: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
    Measure Participants 115 65
    Yes
    3
    2.6%
    1
    1.5%
    No
    112
    97.4%
    64
    98.5%
    Yes
    2
    1.7%
    0
    0%
    No
    113
    98.3%
    65
    100%
    Yes
    60
    52.2%
    30
    46.2%
    No
    55
    47.8%
    35
    53.8%
    Yes
    4
    3.5%
    1
    1.5%
    No
    111
    96.5%
    64
    98.5%
    Yes
    5
    4.3%
    5
    7.7%
    No
    110
    95.7%
    60
    92.3%
    Yes
    10
    8.7%
    1
    1.5%
    No
    105
    91.3%
    64
    98.5%
    Yes
    2
    1.7%
    0
    0%
    No
    113
    98.3%
    65
    100%
    Yes
    9
    7.8%
    5
    7.7%
    No
    106
    92.2%
    60
    92.3%
    6. Secondary Outcome
    Title Disease Free Survival (DFS) Rate at 3 Years
    Description DFS rate is defined as the percentage of participants without local recurrences at 3-years post study treatment. Here we report the DFS rate at 3-years after completing the Study treatment.
    Time Frame At 3 years after study treatment completion, within a general time frame of 5 years and two months

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title mFOLFOX6 + Aflibercept mFOLFOX6
    Arm/Group Description - mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme: Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m². - Aflibercept, will be administered intravenously (I.V.) at doses of 4 mg/Kg on Day 1 every 14 days. Aflibercept will be supplied to sites by the study Sponsor as 4 ml vials at a concentration of 25 mg/ml. Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs. Aflibercept: Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml 5-Fluoruracil: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2 Oxaliplatin: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU Leucovorin: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU - mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme: Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m². Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs. 5-Fluoruracil: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2 Oxaliplatin: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU Leucovorin: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
    Measure Participants 115 65
    Number (95% Confidence Interval) [percentage of participants]
    75.2
    65.4%
    81.5
    125.4%

    Adverse Events

    Time Frame From Baseline to study completion, within an general time frame of 3 years per study protocol
    Adverse Event Reporting Description For the statistical tables, adverse events have been coded according to the Medical Dictionary of Regulatory Activities (MedDRA 20.1) system. Their intensity has been coded by (NCI-CTCAE) v4.0 toxicity criteria. The safety and tolerability of the study therapy were assessed by means of AEs and changes in laboratory data that were reported in the AEs page. Grade 3 or higher AEs were reported as serious. All the grade 1 and 2 as non serious.
    Arm/Group Title mFOLFOX6 + Aflibercept mFOLFOX6
    Arm/Group Description - mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme: Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m². - Aflibercept, will be administered intravenously (I.V.) at doses of 4 mg/Kg on Day 1 every 14 days. Aflibercept will be supplied to sites by the study Sponsor as 4 ml vials at a concentration of 25 mg/ml. Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs. Aflibercept: Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml 5-Fluoruracil: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2 Oxaliplatin: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU Leucovorin: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU - mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme: Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m². Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs. 5-Fluoruracil: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2 Oxaliplatin: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU Leucovorin: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
    All Cause Mortality
    mFOLFOX6 + Aflibercept mFOLFOX6
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 12/115 (10.4%) 7/65 (10.8%)
    Serious Adverse Events
    mFOLFOX6 + Aflibercept mFOLFOX6
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 45/115 (39.1%) 16/65 (24.6%)
    Blood and lymphatic system disorders
    Neutropenia 25/115 (21.7%) 14/65 (21.5%)
    Thrombocytopenia 1/115 (0.9%) 2/65 (3.1%)
    Anemia 1/115 (0.9%) 1/65 (1.5%)
    Gastrointestinal disorders
    Diarrhoea 8/115 (7%) 4/65 (6.2%)
    Mucosal inflamation 4/115 (3.5%) 0/65 (0%)
    Proctalgia 1/115 (0.9%) 1/65 (1.5%)
    Rectal hemorrage 2/115 (1.7%) 0/65 (0%)
    General disorders
    Asthenia 2/115 (1.7%) 0/65 (0%)
    Nausea 0/115 (0%) 1/65 (1.5%)
    Abdominal pain 1/115 (0.9%) 0/65 (0%)
    Dysphonia 1/115 (0.9%) 0/65 (0%)
    Pyrexia 1/115 (0.9%) 0/65 (0%)
    Fatigue 1/115 (0.9%) 0/65 (0%)
    Infections and infestations
    Stomatitis 0/115 (0%) 1/65 (1.5%)
    Nervous system disorders
    Peripheral neuropathy 2/115 (1.7%) 1/65 (1.5%)
    Skin and subcutaneous tissue disorders
    Palmar-plantar erythrodysesthesia syndrome 3/115 (2.6%) 0/65 (0%)
    Vascular disorders
    Hypertension 34/115 (29.6%) 2/65 (3.1%)
    Other (Not Including Serious) Adverse Events
    mFOLFOX6 + Aflibercept mFOLFOX6
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 115/115 (100%) 65/65 (100%)
    Blood and lymphatic system disorders
    Neutropenia 14/115 (12.2%) 4/65 (6.2%)
    Thrombocytopenia 9/115 (7.8%) 7/65 (10.8%)
    Anemia 6/115 (5.2%) 7/65 (10.8%)
    Gastrointestinal disorders
    Diarrhoea 42/115 (36.5%) 22/65 (33.8%)
    Mucosal inflamation 48/115 (41.7%) 14/65 (21.5%)
    Vomiting 21/115 (18.3%) 13/65 (20%)
    Decrease apetite 25/115 (21.7%) 9/65 (13.8%)
    Constipation 13/115 (11.3%) 9/65 (13.8%)
    Proctalgia 11/115 (9.6%) 6/65 (9.2%)
    Rectal hemorrage 14/115 (12.2%) 3/65 (4.6%)
    Anal inflammation 10/115 (8.7%) 0/65 (0%)
    Rectal tenesmus 8/115 (7%) 1/65 (1.5%)
    General disorders
    Asthenia 65/115 (56.5%) 38/65 (58.5%)
    Nausea 37/115 (32.2%) 23/65 (35.4%)
    Abdominal pain 16/115 (13.9%) 5/65 (7.7%)
    Dysphonia 19/115 (16.5%) 1/65 (1.5%)
    Pyrexia 14/115 (12.2%) 4/65 (6.2%)
    Dysgeusia 11/115 (9.6%) 8/65 (12.3%)
    Musculoesqueletal pain 11/115 (9.6%) 7/65 (10.8%)
    Aphonia 14/115 (12.2%) 0/65 (0%)
    Upper abdominal pain 10/115 (8.7%) 3/65 (4.6%)
    Fatigue 7/115 (6.1%) 5/65 (7.7%)
    Headache 8/115 (7%) 1/65 (1.5%)
    Infections and infestations
    stomatitis 14/115 (12.2%) 3/65 (4.6%)
    cystitis 9/115 (7.8%) 7/65 (10.8%)
    Nervous system disorders
    Peripheral neuropathy 48/115 (41.7%) 30/65 (46.2%)
    Dysaesthesia 15/115 (13%) 10/65 (15.4%)
    Paraesthesia 11/115 (9.6%) 11/65 (16.9%)
    Skin and subcutaneous tissue disorders
    Palmar-plantar erythrodysaesthesia syndrome 13/115 (11.3%) 8/65 (12.3%)
    Vascular disorders
    Hypertension 22/115 (19.1%) 3/65 (4.6%)
    Epistaxis 17/115 (14.8%) 1/65 (1.5%)

    Limitations/Caveats

    There are no overall limitations and caveats. In detail: There were 6 patients that received treatment doses that did not matched protocol specifications. These were notified as protocol major deviations to the competent authorities and ethics committees. The effect of these deviations on results is not significant.

    More Information

    Certain Agreements

    Principal Investigators are NOT employed by the organization sponsoring the study.

    There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

    Results Point of Contact

    Name/Title Pau Doñate Macian
    Organization MFAR Clinical Research
    Phone 0034934344412
    Email investigacion@mfar.net
    Responsible Party:
    Grupo Espanol Multidisciplinario del Cancer Digestivo
    ClinicalTrials.gov Identifier:
    NCT02340949
    Other Study ID Numbers:
    • GEMCAD-1402
    First Posted:
    Jan 19, 2015
    Last Update Posted:
    May 3, 2021
    Last Verified:
    Apr 1, 2021